RespireRx Pharmaceuticals Inc (CE) (RSPI) 뉴스

How many shares does each of those two own? TIA

Good point as I would think they would want to see fruit from their endeavors... and their platforms are at a point where they need resources and to be placed in hands more capable to take them into clinicals..

Would make sense with the extra effort on publications the past few years, cementing the past efforts/legacy for posterity.. The execs have provided cash for shares as well as owning preferred shares and they continue to market the preferred shares... which require huge payment events and much higher shareprice for series J to pay out handsomely for their risk/effort. License, partner/JV or sale... That is what they have been setting up their platforms for going on several years now according to filings...

One significant event here will snowball into several significant events, IMO.

Given Lippa and Jeff are far and away the biggest shareholders, I think the timeline for their exit is soon. Lippa is older and I’m sure he would love to see the impact of this for him/family sooner rather than later. He certainly isn’t looking to maintain a CEO pace for much longer. This isn’t something you would put into a corporate communication but I’m sure I’m not far off by guessing this.

I agree. There was ample accumulation of shares before the DOD announcement and subsequent buying surge. And then the two weeks prior to going EM, short-term interests sold out heavily to accumulating interests. The ampakines have a history for sure and moving the premier gabakine to tier 3 NIH has significant value for investors so there is no fooling around, or should not be. I kinda wonder if that isn't why all the business end complaints we have on this forum are just non-chalantly passed over as possibly the most logical forward paths are already in motion... So we hold our shares with gold encrusted hands...

Company communication has continually suggested how undervalued the assets are and with potential breakthrough candidates heading into clinical trials AND quite possibly negotiating upfront cash and huge milestone payments/agreements/partnerships with BP, there probably won't be much stomach for funny business as that is putting a lot at risk unnecessarily...

Now maybe they say hey, how about we just buyout RSPI now for say .10/share We would probably all be happy and have to accept such valuation as "fair" currently.. But we longs would no longer have access to equity ownership in these assets long term which could be many many multiples of buyout price in a few years as success is proven.....

It will be interesting for sure how things are structured...

"potential strategic deal making discussions that commenced in 2024, continue into 2025"... So as KRM-ll-81 is prepping to exit the IND enabling NIH preclinicals, surely working with the NIH, etc question is there something in the works to partner with resources to get phase 1 clinicals underway? This is the purpose of the HEAL initiative correct? Could there be a licensing agreement with cash upfront and milestone payments brewing, similar to other major BP deals? It is notable that they have applied for grant funding for KRM-ll-81 only for epilepsy, and my understanding is this is IND enabling support. Would a BP consider buying out this asset now to take complete control or just license for pain indications only while RSPI preps the compound for epilepsy trials later on? My hunch is BP does not want to deal OTC shenanagins, so maybe they want the entirety of this compound; maybe spin the gabakine program to entirely different entity isolated from ampakines and RSPI?

You read a lot of these BP deals with smaller early stage pharmas as having "access" to premier compounds/candidates... Would love to see us current shareholders get an upfront cash dividend and distribution of equity (for long term growth/milestones) into a newco for the gabakine program. Maybe this is why they want to keep common shares minimal and not add much dilution (so went to the EM) to make each share owned now more valuable in a strategic deal???

One thing about it is that it’s “somewhat” famous in neuroscience. The CX compounds are widely known, and have been used in basic research extensively. Any shady, funny business would be named and shamed instantly.

A number of years ago, I was invested in a small cap biotech which was a one-horse show. Not even close to the potential of RSPI, by a huge shot. They sold out under a very shady deal which left management wealthy and us shareholders in the lurch. I was asked to be a party in a lawsuit which was quickly dropped - perhaps because it wasn't cost effective for the plaintiff firm? Anyway, I am fearful this will happen with RSPI. But I think we all can agree that the value of RSPI is massive and only hope that because RSPI's current valuation is so artificially low that an under-the-table payout to management leaving us shareholders in the lurch does not occur. Well, that is my fear, but with RSPI, I don't see this happening - we have a herd, not a starving horse.

Thanks very much for the insight. It’s very useful indeed

Thanks very much, excellent information!

It's usually done for cash or shares in the acquiring Company or a combination of the two. Shareholders sometimes have options and can even opt out.

In the case at hand I didn't look into the offer.....here's why:
https://www.nasdaq.com/articles/sage-rejects-biogens-offer-buy-remaining-stake-stock

Interesting deal in that Lilly is acquiring an asset while scorpion is spinning out everything else to a new company…

Similar as RSPI is spinning assets into EndeavourRX. I am just wondering which assets are going into EndeavourRX. And will BP jump on licensing or owning the pain candidate as it exits IND enabling?

How is the deal done? In my one buyout it was all about one stupid little patented compounded drug formula that some Japanese company made an offer on after a long and pronounced period of suffering thru lower share prices. This was mostly due to the company financing a large loan sum towards the end that did not make any sense to the shareholders. It didn't smell right to me, so I averaged down a lot and hung on. Months later, the offer was made (which I believe was around 14 Dollars) and the stock price opened right there (minus a few pennies) so the MMs could make a few pennies buying from anyone who wanted to sell before the deal closed. I did not sell because I was hoping for a competing offer (bidding war) but that did not materialize. After the deal closed, maybe 4 or 6 weeks later, the transfer occurred, the symbol disappeared, and the proceeds went to my account's cash balance. Turns out the buyers had demanded cash as part of the deal and that's why the seller took out the crazy large loan with no explanation. The company couldn't say anything about the loan and that was a tipoff for me. Many sold around $1.50 because of that loan. Just one of the multitude of twists that can befall someone holding long. I'm hoping the EM thing here is just another of these tactics.

So in a merger/acquisition where they say they pay 7.22$ per share, for example, how does that work for the existing shareholders? How is the deal done? What happens in the shareholders’ accounts? That never happened to one of my stocks.

Looking good , I would love 7.22 a share here. GLTA

Look at Scorpion Therapeutics - RSPI IMO has more to offer. Lilly is paying 2.5 billion!

In 2025, many biotech companies are expected to be involved in mergers and acquisitions (M&A), including:
Lantheus Holdings: Acquiring Life Molecular Imaging (LMI) for $350 million, plus potential additional payments
Johnson & Johnson: Acquiring Intra-Cellular Therapies
Eli Lilly: Acquiring Scorpion Therapeutics for $2.5 billion
GlaxoSmithKline (GSK): Acquiring IDRx
Salarius Pharmaceuticals: Merging with Decoy Therapeutics
Biogen: Acquiring Sage Therapeutics for $7.22 per share
Vividion Therapeutics: Acquiring Tavros Therapeutics

I need a much bigger green lantern for this thing! LOL

Looks like I'm a little high on the estimate. We want OTCID + the Application fee = $11,000

Attorney fee + TA fees

Needs to be in the TA Verified shares program

How did you arrive at this? "13k to OTCM "
https://www.otcmarkets.com/corporate-services/fee-schedule

"Needs TA Verified and Form 15." ....and up to date financials plus an attorney letter if they're unaudited.

How many more wishes you have left from the lantern? lol

Hopefully you can get your mystery painter to start on the next floors of this high rise. The lobby has many coats of paint on it already...

And even with that price of two and a half pennies, the market valuation would only be 25 million...

Still peanuts for a pharma with this pipeline and multiple candidates, multiple indications in large unmet markets at clinical stage..

Ditto that $$$$. Up 100%. * This ticker could open 1000 % with the right news $$.

RSPI

Whomever painted this .0024 I appreciate that from the bottom of my heart! Portfolio looks awesome at .0024 vs .0012! THANK YOU!!!

Closed .0016 x .0024

Someone tapped the ask

Seems simple enough and good thoughts. Wonder where they get this idea it cost just as much to go alternative reporting?

Seems better route and cost effective and heck maybe they spin out or IPO the subs anyhow and distribute equity down the line..

Agree 100%

Well if cost is the issue, it's best to go Alt Reporting. Pay the 13 grand to OTCM and get trading again. It would trade the same as SEC Reporting but don't need to deal with auditors and all those high expenses, usually 6 figures.

It already lost the 211, OTCM would sponsor it either way.

And a lot of reputable companies choose OTCM reporting until they get back on their feet. It can refile a Form 10 any time.

Yeah seems simple. What advantages are there to stay SEC registered? Reputation? Legitamacy? Sounds like the major funding will take place within the subsidiaries which will have their own financials.. Or do they need to have certain level of financial auditing at the licensor of technology level?

Needs TA Verified and Form 15.

13k to OTCM

Could have the greatest assets in the world, but those 2 things are the most important right now.

I would expect this to take off like it was bound too after the DOD phase 2 news, with the added benefit now that there is likely significant news related to grants, additional funding and bp partnerships all looming.. But yeah, I think they need to announce a strategy to investing public of how they anticipate getting off the EM. Do they want to drop all the filings in a day and have a mad rush bid this up several pennies on the EM? Or will they stagger the filings out and allow for a more steady accumulation/consolidation on the upward trajectory to minimize extreme volatility? Or maybe they just announce a big partnership or funding deal while on the EM with different plans for the equity and create all kinds of havoc for entities to scramble to find shares??

Well the company internally says their assets are worth 50+ million thats .05 today and that may be conservative as KRM-ll-81 exits preclincals/IND enabling for pain.

Doesn't matter, until off the EM this wont really get moving like that..

I couldn't imagine that, but sure would be welcome in my portfolio right about now.

Guarantee if fillings are dropped 1 by 1 leading into the finale day of going current all it would take is a couple of low volume hits are we will open above 006 minimum ran past 01 rather quickly 

Well if one just wants that excitement, bigt usually has some for sale at .05

Then we can really see what coulda shoulda woulda... but probably still shoulda woulda in the not too distant future, assuming they are serious about getting these candidates into clinicals under the best circumstances for success...

No problem. I read alot so the only caveat is the information is only as good as what is found on the internet and well all the A.I. jazz that now convolutes information nowdays...

Thanks for all the details it’s appreciated

GTA

Hmmm I have a bid at .0015?

Thanks for posting the bid and ask here Lime Time! It's much appreciated!

I can't argue with you as you are 100% correct including the Dopamine effect! LOL

What's the point even if 002 it's an illusion till back on the market. The price jump just deludes our senses for a brisk hit of dopamine lol

.0013 x .0024

I am assuming it's still .002 or higher?

I wish someone would just tap the ask for just 100 shares just to get us out of these .0012's and back into the .002's. Especially before the close. I would do it in a heartbeat but I cannot buy expert market stocks in the U.S. These .0012's suck in the portfolio.

From what I read they can go back and forth for months on end negotiating and such before any final determination is made to strip of SEC registration and then there is still an appeal process, etc, etc. And after all that additional embarassment they could then go alternative reporting route onto the pink market. One would think having important dealings with both DOD and NIH would add a few points to allow plenty leeway for the "management" to get their xxxx together...

It truly is unbelieveable they are at this point having investors and potential investors/partners having to concern themselves with this foolishness. Announce a plan to get off the expert market and follow through so they can get on with establishing the foundations to build out resources and partnerships needed for this significant pipeline.

"Together, we can advance life-changing therapies, create value for our investors, and positively impact the lives of patients worldwide." Looking forward to it!!

Last time I hit Jeff up , they were waiting to hear back from the SEC .

What’s happening with the revocation notice? Are we past the delay?

"They went through all that effort, going the extra mile… "

Yes. Commendable. Thoughtful. Investors seek quality in this regards and should explain why there are not many shares available at these depressed levels as stakeholders in pharma can see the progress and accomplishments and understand the potential to be breakthrough on multiple levels in multiple lanes is exciting for all...

Yet... "neglect", "stupid issue holds them back"... Why is this? Incompetance? OTC shenanigans? Poor Advisory? This is embarrassing and upsetting and there are really no excuses.....

Despite it all... "lovely little book project." we all still envision a great story stock emerging from the shadows.

Look at the bright side. No fraud, no scam, no BS.
They have real, tangible, legitimate, enforceable assets, real science, which their small core group of collaborators have fleshed out in a particularly thorough and obstinate way, such that any dirty fat fingers trying to help themselves will be named and shamed and booed.

They went through all that effort, going the extra mile… For a reason. It aligns with their values, and the foundation of their motivation, which also leads them to neglect certain things that are necessary to do well in business. Otherwise they would not be so undervalued. They would not be in that situation.
And it’s quite interesting to see that some stupid issue holds them back pretty hard. Because it says more about the system than them.
So after all is resolved and they are vindicated this will be a lovely little book project.

Why on Earth they let this go to the EM and is still on the EM is beyond me...
The shareholder letter was perfect in defining what they have going on and where they see themselves going.

Truly the picture of consistency. I don't get it.